EP2046313A4 - Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie - Google Patents

Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie

Info

Publication number
EP2046313A4
EP2046313A4 EP07769053A EP07769053A EP2046313A4 EP 2046313 A4 EP2046313 A4 EP 2046313A4 EP 07769053 A EP07769053 A EP 07769053A EP 07769053 A EP07769053 A EP 07769053A EP 2046313 A4 EP2046313 A4 EP 2046313A4
Authority
EP
European Patent Office
Prior art keywords
naphthoquinones
hyperglycemia
diabetes
treatment
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07769053A
Other languages
English (en)
French (fr)
Other versions
EP2046313A1 (de
Inventor
Mona Wilcke
Bo Svensson
Bjoern Walse
Tore Bengtsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glucox Biotech AB
Original Assignee
Glucox Biotech AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glucox Biotech AB filed Critical Glucox Biotech AB
Publication of EP2046313A1 publication Critical patent/EP2046313A1/de
Publication of EP2046313A4 publication Critical patent/EP2046313A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07769053A 2006-07-10 2007-07-06 Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie Withdrawn EP2046313A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0601503 2006-07-10
SE0602611 2006-12-04
PCT/SE2007/050507 WO2008008033A1 (en) 2006-07-10 2007-07-06 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia

Publications (2)

Publication Number Publication Date
EP2046313A1 EP2046313A1 (de) 2009-04-15
EP2046313A4 true EP2046313A4 (de) 2012-01-25

Family

ID=38923504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07769053A Withdrawn EP2046313A4 (de) 2006-07-10 2007-07-06 Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie

Country Status (2)

Country Link
EP (1) EP2046313A4 (de)
WO (1) WO2008008033A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9895344B2 (en) 2008-07-25 2018-02-20 Emory University Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
US9040713B2 (en) 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
JP6280050B2 (ja) * 2012-12-26 2018-02-14 中島　利博 肥満症予防又は治療剤，リウマチの予防又は治療剤
US20150344404A1 (en) * 2012-12-26 2015-12-03 The Kitasato Institue Pdk4 inhibitor and use thereof
KR101760565B1 (ko) 2015-06-10 2017-07-31 포항공과대학교 산학협력단 Tenc1의 활성 억제제를 유효성분으로 포함하는 당뇨병성 근위축증의 예방 또는 치료용 약학적 조성물
KR102034243B1 (ko) * 2016-07-05 2019-10-21 바스테라 주식회사 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
KR102032739B1 (ko) * 2018-01-31 2019-10-16 한림대학교 산학협력단 신규한 크리신 유도체 화합물을 유효성분으로 포함하는 당뇨합병증의 예방 또는 치료용 약학 조성물
CN116869980A (zh) * 2023-08-01 2023-10-13 中国药科大学 胡桃醌在制备治疗和/或预防脂质代谢异常疾病药物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (de) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Proteische-ADP-Ribosidierung hemmende Stoffe geeignet zum Vorbeugen der Diabetes-Mellitus-Komplikationen
EP0659883A2 (de) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 und dafür kodierende DNS
JPH1045575A (ja) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd シコニン含有ｈｓｐ４７合成抑制剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060070135A1 (en) * 1998-07-24 2006-03-30 Michel Tremblay Compositions and methods for inhibiting the enzymatic activity of PTP-1B
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
EP1435930A2 (de) * 2001-10-15 2004-07-14 National Research Council Of Canada Glykierungsinhibitoren zur prävention von komplikationen des alters, der diabetes und des rauchens
JP2005523004A (ja) * 2002-04-17 2005-08-04 グルコックス アーベー グルコース取り込みの増加及びｉｉ型糖尿病の治療のためのｎａｄ（ｐ）ｈオキシダーゼ阻害剤
KR20050036293A (ko) * 2003-10-15 2005-04-20 동아제약주식회사 나프토퀴논계 화합물을 함유한 세포질형 이소시트릭산탈수소화효소 활성 저해제 및 비만과 고지혈증 예방 또는치료용 약학적 조성물
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
EP1746984A2 (de) * 2004-05-06 2007-01-31 Robert F. Hofmann Verwendung einer gezielten oxidativen therapeutischen formulierung bei der behandlung von diabetes und fettsucht

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (de) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Proteische-ADP-Ribosidierung hemmende Stoffe geeignet zum Vorbeugen der Diabetes-Mellitus-Komplikationen
EP0659883A2 (de) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 und dafür kodierende DNS
JPH1045575A (ja) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd シコニン含有ｈｓｐ４７合成抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199817, Derwent World Patents Index; AN 1998-189155, XP002665579 *
REIKO KAMEIA ET AL: "Shikonin Stimulates Glucose Uptake in 3T3-L1 Adipocytes via an Insulin-Independent Tyrosine Kinase Pathway", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 292, no. 3, 5 April 2002 (2002-04-05), pages 642 - 651, XP008102880, ISSN: 0006-291X, [retrieved on 20020402], DOI: 10.1006/BBRC.2002.6714 *
See also references of WO2008008033A1 *

Also Published As

Publication number Publication date
EP2046313A1 (de) 2009-04-15
WO2008008033A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
EP2048152A4 (de) Spiroketalderivate mit kondensiertem ring und dessen verwendung als arzneimittel zur behandlung von diabetes
HUE038279T2 (hu) Klotho-béta-agonista antitest cukorbetegség vagy inzulinrezisztencia kezelésében történõ alkalmazásra
DK2419097T3 (da) Farmaceutisk sammensætning omfattende (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol og metformin og anvendelser deraf i behandling af diabetes
DK2091599T3 (da) Forbedringer af og vedrørende drivmekanismer, der er egnet til anvendelse i anordninger til lægemiddelfremføring
ATE502960T1 (de) Lingo bindende moleküle und pharmazeutische verwendung davon
EP2061531A4 (de) Intravaskuläre blutpumpe und katheter
PL3542869T3 (pl) Jednorazowy monitor snu i oddechu
EP2424507A4 (de) Zusammensetzungen und verfahren zur behandlung von insulinresistenz und diabetes mellitus
BRPI0923169A2 (pt) "composição de pasta sensível à pressão, e, dispositivo médico"
BRPI0820581A2 (pt) Dispositivo de interface com paciente, e, cânula nasal
ZA200704000B (en) Total patient input monitoring
WO2009051706A3 (en) Peptide compounds for treating obesity and insulin resistance
IL193800A0 (en) Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
EP2036574A4 (de) Medizinisches mittel zur behandlung von fettsucht, diabetes und erkrankungen im zusammenhang mit beeinträchtigter glucosetoleranz
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
EP2073832A4 (de) Untercarboxyliertes/uncarboxyliertes osteocalcin für erhöhte betazellen-proliferation, insulinausscheidung, insulinempfindlichkeit und glucosetoleranz sowie zur fettreduzierung
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
DK2407474T3 (da) Triacetyl-3-hydroxyfenyladenosin og dets anvendelse til regulering af blodfedt
IL240118A0 (en) Biological glue without thrombin and its use as a medicine
GB0717100D0 (en) Surgical and medical garments and materials incorporating shear thickening fluids
EP1974685A4 (de) Verweil-medizinprodukt
EP2036566A4 (de) Verwendung von 20(s)-protopanoxadiol bei der herstellung von antidepressiva
IL202351A0 (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
ATE504595T1 (de) Il-22 zur behandlung von fettleibigkeit, diabetes,hyperlipidämie, hyperglykämie und insulinresistenz
EP1890708A4 (de) Glucose-induzierbare insulinexpression und behandlungsmethoden für diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20111227

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/08 20060101ALN20111219BHEP

Ipc: A61P 3/06 20060101ALN20111219BHEP

Ipc: A61P 3/04 20060101ALN20111219BHEP

Ipc: A61P 3/10 20060101ALI20111219BHEP

Ipc: A61K 31/37 20060101ALI20111219BHEP

Ipc: A61K 31/122 20060101AFI20111219BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503